ICTCAR003

ICTCAR003 is an investigational **autologous CD19-directed CAR-T cell therapy** being developed by Innovative Cellular Therapeutics for the treatment of **B-cell acute lymphoblastic leukemia**. The product is made by collecting a patient's T cells, genetically modifying them ex vivo to express a chimeric antigen receptor that recognizes **CD19** on malignant B cells, and reinfusing the engineered cells to drive targeted immune-mediated killing of CD19-positive leukemia cells. It has been described as Innovative Cellular Therapeutics' lead CAR-T candidate in China, and no brand name has been identified.

Other names

CD19-targeting CAR-TCD-19-targeting CAR-TCD 19-targeting CAR-TCD19-targeted chimeric antigen receptor T-cell therapyCD-19-targeted chimeric antigen receptor T-cell therapyCD 19-targeted chimeric antigen receptor T-cell therapy